Immune-related adverse events of checkpoint inhibitors
Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …
Endocrine toxicities of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis
Importance If not promptly recognized, endocrine dysfunction can be life threatening. The
incidence and risk of develo** such adverse events (AEs) following the use of immune …
incidence and risk of develo** such adverse events (AEs) following the use of immune …
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies
DJ Byun, JD Wolchok, LM Rosenberg… - Nature Reviews …, 2017 - nature.com
Advances in cancer therapy in the past few years include the development of medications
that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and …
that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and …
[HTML][HTML] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-
L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained …
L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained …
Thyroid immune-related adverse events following immune checkpoint inhibitor treatment
Context Thyroid dysfunction occurs commonly following immune checkpoint inhibition. The
etiology of thyroid immune-related adverse events (irAEs) remains unclear and clinical …
etiology of thyroid immune-related adverse events (irAEs) remains unclear and clinical …
[HTML][HTML] A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors
Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
A Bertrand, M Kostine, T Barnetche, ME Truchetet… - BMC medicine, 2015 - Springer
Background Targeting CTLA-4 is a recent strategic approach in cancer control: blocking
CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T …
CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T …
Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects
LA Dalvin, CL Shields, M Orloff, T Sato, JA Shields - Retina, 2018 - journals.lww.com
Purpose: To review immune checkpoint inhibitor indications and ophthalmic side effects.
Methods: A literature review was performed using a PubMed search for publications …
Methods: A literature review was performed using a PubMed search for publications …
Prospects of immune checkpoint modulators in the treatment of glioblastoma
Glioblastoma is the most common primary brain tumour in adults. Prognosis is poor: even
with the current gold-standard first-line treatment—maximal safe resection and combination …
with the current gold-standard first-line treatment—maximal safe resection and combination …